Compare NCMI & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NCMI | PRTC |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 464.3M |
| IPO Year | 2007 | N/A |
| Metric | NCMI | PRTC |
|---|---|---|
| Price | $3.82 | $19.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.63 | N/A |
| AVG Volume (30 Days) | ★ 269.2K | 2.9K |
| Earning Date | 03-05-2026 | 08-28-2025 |
| Dividend Yield | ★ 3.15% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $236,300,000.00 | $6,391,000.00 |
| Revenue This Year | $3.27 | N/A |
| Revenue Next Year | $11.61 | N/A |
| P/E Ratio | ★ N/A | $8.57 |
| Revenue Growth | N/A | ★ 1265.60 |
| 52 Week Low | $3.68 | $13.30 |
| 52 Week High | $7.25 | $20.00 |
| Indicator | NCMI | PRTC |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 52.17 |
| Support Level | $3.72 | $17.31 |
| Resistance Level | $3.96 | $18.82 |
| Average True Range (ATR) | 0.14 | 0.66 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 30.00 | 34.47 |
National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.